How a secretin-family peptide binds its receptor in two steps, and why the amino terminus must be intact

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The receptors for growth hormone-releasing hormone, glucagon, GLP-1, secretin and their relatives share an architecture: a large amino-terminal extracellular domain of about 120 residues and a seven-helix transmembrane core. The two-domain model, developed in the 1990s and confirmed by crystal and cryo-electron microscopy structures of several family members from 2017 onward, holds that the carboxyl-terminal helix of the peptide binds the extracellular domain first, positioning the peptide so that its amino terminus can insert into the core and trigger the conformational change that activates the G protein. A peptide missing its first two residues binds the extracellular domain and does nothing — which is exactly what GHRH 3-44 does, and why the hexenoyl protection matters.

The two steps

Affinity comes mostly from the first step: the helical body of the peptide lying along a groove in the extracellular domain. Activation comes from the second: the amino-terminal residues reaching deep into the helical bundle and contacting residues that shift the sixth helix outward. Separating the two explains why truncated peptides can be antagonists and why the activating residues are so conserved across the family.

The GHRH receptor itself has been less studied structurally than the GLP-1 and glucagon receptors, but the family conservation is strong.

The structures

Full-length structures of the glucagon and GLP-1 receptors with peptide bound showed the peptide helix bridging the extracellular domain and the core, confirming the model and showing the activating residues in place. A GHRH receptor structure reported in 2020 fitted the same picture. The structures explain the pharmacology of the whole class, including the long-acting GLP-1 agonists described on the Retatrutide pages.

Tesamorelin is expected to bind as native hormone does, with the acyl group outside the core.

Why it is here

Because the receptor mechanism is the reason a two-residue cleavage inactivates the hormone and the reason the analogue was built as it was. It describes receptor biology and no use of the pack.

Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Tesamorelin Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The two steps?

Affinity comes mostly from the first step: the helical body of the peptide lying along a groove in the extracellular domain. Activation comes from the second: the amino-terminal residues reaching deep into the helical bundle and contacting residues that shift the sixth helix outward. Separating the two explains why truncated peptides can be antagonists and why the activating residues are so conserved across the family.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Tesamorelin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.